Latest Going Concern News

Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.

Sparc Technologies Limited reported a significant net loss of $1.86 million for the half-year ended December 2025, highlighting ongoing financial pressures despite continued R&D efforts. The company flagged material uncertainty over its ability to continue as a going concern.

Atomos Limited has reported a profitable first half of FY26 with revenue up 28%, driven by strong sales and cost discipline. The company reaffirms its full-year guidance, anticipating further growth and positive cash flow in the second half.

Elanor Investors Group reported a $24.5 million net loss for the half year to December 2024, grappling with debt covenant breaches and defaults. The group has struck a $125 million recapitalisation agreement with Rockworth Capital Partners to stabilise its balance sheet and pursue growth.

Lumos Diagnostics reported a 74% increase in its half-year loss to US$4.88 million, despite strong progress with its FebriDx diagnostic test and a landmark US distribution agreement. The company awaits a critical FDA decision that could unlock significant revenue growth.

Rubicon Water reported a 9.4% revenue decline to $29 million and a net loss of $6.4 million in the first half of FY26, driven by a sharp drop in ANZ hardware sales. The company anticipates a rebound in Asia in the second half, despite ongoing foreign exchange headwinds.

Entropy Neurodynamics reports a 14.8% reduction in half-year losses while progressing a pioneering clinical trial for Binge Eating Disorder using its proprietary psychedelic drug TRP-8803. The company also secured $6.1 million in new funding and strategic collaborations to enhance its neuropsychiatry platform.

Hydrix Limited reported a 14% revenue decline and a sharp increase in net loss for H1 2026, raising concerns about its financial stability despite securing a major contract.

Novatti Group Limited has reported a striking turnaround to a $3.8 million profit in the first half of 2026, despite a 42% drop in revenue. The fintech’s strategic divestments and reclassification of its AUDC investment signal a pivotal shift in its growth trajectory.

Mesoblast Limited reported its first commercial sales of FDA-approved Ryoncil, generating $48.7 million in net product sales for the half-year ended December 31, 2025, while reducing its net loss by 16%. The company also secured a $125 million five-year credit facility, restructuring its debt to support ongoing commercialization and development.

Weebit Nano Limited has reported a remarkable 8-fold increase in revenue, driven by a landmark licensing agreement with Texas Instruments and significant progress in its ReRAM technology commercialisation.

Polymetals Resources has reported its maiden revenue from the Endeavor Mine with first concentrate shipments, yet posted a substantial half-year loss of $34.5 million. Operational setbacks and exploration advances mark a pivotal phase for the company.